Vasopressin is a hormone used to treat a variety of conditions, including low blood pressure, diabetes insipidus, and gastrointestinal bleeding. In the United States, the vasopressin market is primarily driven by the increasing prevalence of chronic diseases and growing geriatric population. The market is highly competitive, with several players offering vasopressin products, including generics. The market is also characterized by high research and development investments, which are driving the development of new formulations and delivery methods. However, regulatory issues, such as the FDA's recent warning about the use of high doses of vasopressin in cardiac arrest patients, may have a negative impact on market growth. Overall, the U.S. vasopressin market is expected to continue to grow in the coming years, driven by increasing demand for vasopressin-based therapies.
U.S. Vasopressin Market
The is estimated to be valued at US$ 894.6 Mn in 2021, and is expected to exhibit a CAGR of 14.7% over the forecast period (2021-2028).
Market Players in the U.S. Vasopressin Industry:
Par Pharmaceutical
Par Pharmaceutical is a generic drug manufacturing company founded in 1978 and headquartered in Chestnut Ridge, New York. The company operates in several countries worldwide, including the United States, Canada, and Australia.
Pfizer Inc.
Pfizer Inc. is a multinational pharmaceutical company that was founded in 1849 and is headquartered in New York City. The company operates in over 150 countries worldwide, including the United States, Canada, and the United Kingdom. In January, 2023 Gero announced that it has entered into a research collaboration with Pfizer to apply Gero’s machine learning technology platform to discover potential therapeutic targets for fibrotic diseases using large-scale human-based data.
Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company founded in 2007 and headquartered in Woodcliff Lake, New Jersey. The company operates in the United States.
Astellas Pharma Inc.
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company founded in 2005 and headquartered in Tokyo, Japan. The company operates in over 70 countries worldwide, including the United States, Canada, and the United Kingdom. In March, 2023 Astellas Pharma Inc. announced that it has entered into an agreement with Roche Diabetes Care Japan Co., Ltd. for the development and commercialization of Roche Diabetes Care's world-renowned Accu-Chek® Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar